<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992159</url>
  </required_header>
  <id_info>
    <org_study_id>20101291</org_study_id>
    <nct_id>NCT01992159</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with romosozumab increases bone
      mineral density in Japanese women with postmenopausal osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2012</start_date>
  <completion_date type="Actual">June 17, 2015</completion_date>
  <primary_completion_date type="Actual">October 9, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)</measure>
    <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)</measure>
    <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Osteocalcin</measure>
    <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)</measure>
    <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Through Month 12 of P1NP</measure>
    <time_frame>Baseline, week 1 and months 1, 2, 3, 6, 9, and 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Postmenopausal Osteoporosis (PMO)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 210 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Romosozumab 140 mg</arm_group_label>
    <arm_group_label>Romosozumab 210 mg</arm_group_label>
    <arm_group_label>Romosozumab 70 mg</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Ambulatory, postmenopausal Japanese women with osteoporosis (defined as bone mineral
        density T-score of ≤ -4.00 at the lumbar spine or BMD T-score of ≤ -3.50 at the total hip,
        or femoral neck)

        Exclusion Criteria:

          -  Severe osteoporosis

          -  Use of agents affecting bone metabolism

          -  History of metabolic or bone disease (except osteoporosis)

          -  Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)

          -  Current hyper- or hypocalcemia

          -  Current, uncontrolled hyper- or hypothyroidism

          -  Current, uncontrolled hyper- or hypoparathyroidism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anjyo-shi</city>
        <state>Aichi</state>
        <zip>446-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0165</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>800-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa-shi</city>
        <state>Fukuoka</state>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mizunami-shi</city>
        <state>Gifu</state>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>063-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>065-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>223-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>231-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>981-3132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>983-0862</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saito-shi</city>
        <state>Miyazaki</state>
        <zip>881-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-1401</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ueda-shi</city>
        <state>Nagano</state>
        <zip>386-0151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ueda-shi</city>
        <state>Nagano</state>
        <zip>386-0405</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>559-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>569-1123</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kita-adachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiyose-shi</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>146-0094</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <zip>166-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. Bone. 2017 Oct;103:209-215. doi: 10.1016/j.bone.2017.07.005. Epub 2017 Jul 5.</citation>
    <PMID>28687496</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>November 20, 2018</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2019</results_first_posted>
  <disposition_first_submitted>September 11, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2015</disposition_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 24 centers in Japan. The first participant was enrolled on 12 October 2012 and the last participant enrolled on 15 October 2013.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1:1:1 ratio to receive placebo or romosozumab 70, 140, or 210 mg subcutaneous (SC) injection every month (QM) for 12 months. Upon completion of the 12-month treatment period, participants were followed for another 3 months for assessment of antiromosozumab antibody formation (follow-up period).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Romosozumab 70 mg</title>
          <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Romosozumab 140 mg</title>
          <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="P4">
          <title>Romosozumab 210 mg</title>
          <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed First 12 Months of Study</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Romosozumab 70 mg</title>
          <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Romosozumab 140 mg</title>
          <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="B4">
          <title>Romosozumab 210 mg</title>
          <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="7.2"/>
                    <measurement group_id="B2" value="66.5" spread="6.3"/>
                    <measurement group_id="B3" value="68.4" spread="6.0"/>
                    <measurement group_id="B4" value="68.3" spread="5.9"/>
                    <measurement group_id="B5" value="67.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 to &lt; 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar Spine Bone Mineral Density (BMD) T-score</title>
          <description>The T-score is the bone mineral density (BMD) at the site when compared to that of a healthy thirty-year-old. Normal is a T-score of −1.0 or higher; Osteopenia is defined as between −1.0 and −2.5; Osteoporosis is defined as −2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.69" spread="0.52"/>
                    <measurement group_id="B2" value="-2.73" spread="0.57"/>
                    <measurement group_id="B3" value="-2.65" spread="0.66"/>
                    <measurement group_id="B4" value="-2.72" spread="0.42"/>
                    <measurement group_id="B5" value="-2.70" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Hip BMD T-score</title>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.00" spread="0.60"/>
                    <measurement group_id="B2" value="-1.97" spread="0.57"/>
                    <measurement group_id="B3" value="-1.85" spread="0.68"/>
                    <measurement group_id="B4" value="-1.95" spread="0.65"/>
                    <measurement group_id="B5" value="-1.94" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Femoral Neck BMD T-score</title>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.31" spread="0.47"/>
                    <measurement group_id="B2" value="-2.27" spread="0.53"/>
                    <measurement group_id="B3" value="-2.28" spread="0.65"/>
                    <measurement group_id="B4" value="-2.32" spread="0.59"/>
                    <measurement group_id="B5" value="-2.29" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Procollagen Type 1 N-telopeptide (P1NP)</title>
          <population>Participants with available data</population>
          <units>μg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="62"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" lower_limit="41.9" upper_limit="62.9"/>
                    <measurement group_id="B2" value="51.9" lower_limit="40.5" upper_limit="59.8"/>
                    <measurement group_id="B3" value="47.6" lower_limit="37.7" upper_limit="54.9"/>
                    <measurement group_id="B4" value="50.9" lower_limit="38.0" upper_limit="59.1"/>
                    <measurement group_id="B5" value="50.5" lower_limit="38.6" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Type 1 Collagen C-telopeptide (CTX)</title>
          <units>ng/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441.0" lower_limit="294.0" upper_limit="692.0"/>
                    <measurement group_id="B2" value="441.0" lower_limit="289.0" upper_limit="678.0"/>
                    <measurement group_id="B3" value="374.0" lower_limit="265.0" upper_limit="552.0"/>
                    <measurement group_id="B4" value="420.0" lower_limit="297.0" upper_limit="690.0"/>
                    <measurement group_id="B5" value="412.0" lower_limit="288.5" upper_limit="628.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Osteocalcin</title>
          <units>μg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.17" lower_limit="17.76" upper_limit="28.74"/>
                    <measurement group_id="B2" value="22.50" lower_limit="17.70" upper_limit="28.46"/>
                    <measurement group_id="B3" value="21.01" lower_limit="16.95" upper_limit="24.35"/>
                    <measurement group_id="B4" value="22.75" lower_limit="18.07" upper_limit="27.12"/>
                    <measurement group_id="B5" value="22.03" lower_limit="17.83" upper_limit="27.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Specific Alkaline Phosphatase (BSAP)</title>
          <population>Participants with available data</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="62"/>
                    <count group_id="B3" value="63"/>
                    <count group_id="B4" value="63"/>
                    <count group_id="B5" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.49" lower_limit="12.26" upper_limit="17.56"/>
                    <measurement group_id="B2" value="13.92" lower_limit="11.53" upper_limit="17.82"/>
                    <measurement group_id="B3" value="15.49" lower_limit="11.85" upper_limit="17.90"/>
                    <measurement group_id="B4" value="14.72" lower_limit="11.45" upper_limit="17.28"/>
                    <measurement group_id="B5" value="14.72" lower_limit="11.85" upper_limit="17.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine</title>
        <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement (primary efficacy subset).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine</title>
          <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement (primary efficacy subset).</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="1.8"/>
                    <measurement group_id="O2" value="8.4" lower_limit="7.6" upper_limit="9.3"/>
                    <measurement group_id="O3" value="13.3" lower_limit="12.1" upper_limit="14.5"/>
                    <measurement group_id="O4" value="16.9" lower_limit="15.5" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the lumbar spine as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>P-values were adjusted for multiplicity using a combination of a sequential test procedure and Hochberg’s method to control type 1 error for the primary endpoint.</p_value_desc>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the lumbar spine as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>P-values were adjusted for multiplicity using a combination of a sequential test procedure and Hochberg’s method to control type 1 error for the primary endpoint.</p_value_desc>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>11.1</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the lumbar spine as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>One-sided p-values were adjusted for multiplicity using a combination of a sequential test procedure and Hochberg’s method to control type 1 error for the primary endpoint.</p_value_desc>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>14.6</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine</title>
        <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine</title>
          <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="6.5" lower_limit="5.7" upper_limit="7.2"/>
                    <measurement group_id="O3" value="10.2" lower_limit="9.2" upper_limit="11.2"/>
                    <measurement group_id="O4" value="13.1" lower_limit="11.7" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the lumbar spine as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>4.4</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the lumbar spine as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>8.0</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the lumbar spine as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>10.6</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip</title>
        <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip</title>
          <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.7" upper_limit="2.9"/>
                    <measurement group_id="O4" value="3.2" lower_limit="2.5" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the total hip as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1250</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the total hip as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the total hip as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip</title>
        <description>Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip</title>
          <description>Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.4" upper_limit="2.8"/>
                    <measurement group_id="O3" value="3.2" lower_limit="2.6" upper_limit="3.9"/>
                    <measurement group_id="O4" value="4.7" lower_limit="4.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the total hip as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the total hip as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the total hip as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck</title>
        <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck</title>
          <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-0.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.1" upper_limit="1.8"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.0" upper_limit="2.9"/>
                    <measurement group_id="O4" value="3.3" lower_limit="2.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the femoral neck as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2846</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the femoral neck as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0151</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the femoral neck as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck</title>
        <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck</title>
          <description>Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.</description>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, and had at least 1 postbaseline measurement.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.6" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.0" upper_limit="2.7"/>
                    <measurement group_id="O3" value="2.9" lower_limit="2.1" upper_limit="3.8"/>
                    <measurement group_id="O4" value="3.8" lower_limit="2.7" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the femoral neck as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the femoral neck as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a repeated measures model with the percent change from baseline at months 6 and 12 in BMD of the femoral neck as the dependent variable, and baseline BMD, machine type, interaction of baseline BMD and machine type, visit (categorical), treatment (categorical), and interaction of treatment and visit as the independent variables; using an unstructured variance covariance structure.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Treatment Difference</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)</title>
        <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)</title>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement and with available data at each time point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="9.0"/>
                    <measurement group_id="O2" value="43.4" spread="24.0"/>
                    <measurement group_id="O3" value="65.9" spread="25.7"/>
                    <measurement group_id="O4" value="81.5" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="22.1"/>
                    <measurement group_id="O2" value="32.2" spread="22.9"/>
                    <measurement group_id="O3" value="79.8" spread="41.7"/>
                    <measurement group_id="O4" value="101.6" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="18.5"/>
                    <measurement group_id="O2" value="-0.7" spread="18.4"/>
                    <measurement group_id="O3" value="34.6" spread="38.2"/>
                    <measurement group_id="O4" value="59.8" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="20.3"/>
                    <measurement group_id="O2" value="-13.1" spread="18.3"/>
                    <measurement group_id="O3" value="14.9" spread="32.2"/>
                    <measurement group_id="O4" value="25.5" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="23.3"/>
                    <measurement group_id="O2" value="-16.8" spread="26.0"/>
                    <measurement group_id="O3" value="-2.7" spread="28.0"/>
                    <measurement group_id="O4" value="2.4" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="32.0"/>
                    <measurement group_id="O2" value="-16.9" spread="31.3"/>
                    <measurement group_id="O3" value="-9.1" spread="30.9"/>
                    <measurement group_id="O4" value="-4.0" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="37.9"/>
                    <measurement group_id="O2" value="-11.1" spread="29.8"/>
                    <measurement group_id="O3" value="-16.2" spread="27.4"/>
                    <measurement group_id="O4" value="-13.1" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)</title>
        <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)</title>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement, and with available data at each time point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="27.8"/>
                    <measurement group_id="O2" value="-28.0" spread="25.8"/>
                    <measurement group_id="O3" value="-32.1" spread="32.8"/>
                    <measurement group_id="O4" value="-42.0" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="40.2"/>
                    <measurement group_id="O2" value="-18.0" spread="34.3"/>
                    <measurement group_id="O3" value="-8.0" spread="53.9"/>
                    <measurement group_id="O4" value="-24.6" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="41.6"/>
                    <measurement group_id="O2" value="-2.3" spread="48.4"/>
                    <measurement group_id="O3" value="14.9" spread="67.8"/>
                    <measurement group_id="O4" value="0.1" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="49.0"/>
                    <measurement group_id="O2" value="-5.5" spread="48.3"/>
                    <measurement group_id="O3" value="28.9" spread="84.1"/>
                    <measurement group_id="O4" value="8.1" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="49.8"/>
                    <measurement group_id="O2" value="-10.8" spread="52.2"/>
                    <measurement group_id="O3" value="3.2" spread="71.8"/>
                    <measurement group_id="O4" value="-13.4" spread="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="56.6"/>
                    <measurement group_id="O2" value="-13.2" spread="53.0"/>
                    <measurement group_id="O3" value="-8.0" spread="55.7"/>
                    <measurement group_id="O4" value="-15.3" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="81.7"/>
                    <measurement group_id="O2" value="-4.1" spread="47.2"/>
                    <measurement group_id="O3" value="2.1" spread="73.5"/>
                    <measurement group_id="O4" value="-10.5" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Osteocalcin</title>
        <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Osteocalcin</title>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement, and with available data at each time point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="18.1"/>
                    <measurement group_id="O2" value="6.5" spread="12.6"/>
                    <measurement group_id="O3" value="7.9" spread="17.0"/>
                    <measurement group_id="O4" value="5.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="12.7"/>
                    <measurement group_id="O2" value="26.5" spread="20.4"/>
                    <measurement group_id="O3" value="51.2" spread="31.9"/>
                    <measurement group_id="O4" value="66.4" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="13.4"/>
                    <measurement group_id="O2" value="13.7" spread="15.1"/>
                    <measurement group_id="O3" value="39.3" spread="31.6"/>
                    <measurement group_id="O4" value="48.9" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="16.8"/>
                    <measurement group_id="O2" value="4.9" spread="17.5"/>
                    <measurement group_id="O3" value="28.4" spread="29.7"/>
                    <measurement group_id="O4" value="27.5" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="15.9"/>
                    <measurement group_id="O2" value="-5.5" spread="18.8"/>
                    <measurement group_id="O3" value="10.6" spread="24.7"/>
                    <measurement group_id="O4" value="9.3" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="18.2"/>
                    <measurement group_id="O2" value="-6.8" spread="22.5"/>
                    <measurement group_id="O3" value="-0.9" spread="24.0"/>
                    <measurement group_id="O4" value="-1.3" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="20.6"/>
                    <measurement group_id="O2" value="-8.6" spread="21.8"/>
                    <measurement group_id="O3" value="-9.4" spread="22.1"/>
                    <measurement group_id="O4" value="-8.9" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)</title>
        <time_frame>Baseline, week 1, and months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)</title>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, never received any dose of incorrect treatment, had no missing baseline values, had at least 1 postbaseline measurement, and with available data at each time point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="13.4"/>
                    <measurement group_id="O2" value="14.0" spread="14.5"/>
                    <measurement group_id="O3" value="17.0" spread="16.4"/>
                    <measurement group_id="O4" value="20.1" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="22.1"/>
                    <measurement group_id="O2" value="23.0" spread="19.9"/>
                    <measurement group_id="O3" value="51.3" spread="27.6"/>
                    <measurement group_id="O4" value="66.2" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="16.9"/>
                    <measurement group_id="O2" value="8.7" spread="20.8"/>
                    <measurement group_id="O3" value="31.8" spread="27.9"/>
                    <measurement group_id="O4" value="55.1" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="16.3"/>
                    <measurement group_id="O2" value="-2.8" spread="14.9"/>
                    <measurement group_id="O3" value="23.5" spread="26.5"/>
                    <measurement group_id="O4" value="39.6" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="20.5"/>
                    <measurement group_id="O2" value="-9.0" spread="19.0"/>
                    <measurement group_id="O3" value="3.1" spread="21.6"/>
                    <measurement group_id="O4" value="13.2" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="20.5"/>
                    <measurement group_id="O2" value="-10.7" spread="21.7"/>
                    <measurement group_id="O3" value="-2.6" spread="25.3"/>
                    <measurement group_id="O4" value="3.5" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="22.7"/>
                    <measurement group_id="O2" value="-13.2" spread="19.9"/>
                    <measurement group_id="O3" value="-13.7" spread="23.3"/>
                    <measurement group_id="O4" value="-9.3" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Through Month 12 of P1NP</title>
        <time_frame>Baseline, week 1 and months 1, 2, 3, 6, 9, and 12.</time_frame>
        <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, had never received any dose of incorrect treatment, and had no missing P1NP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg</title>
            <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 140 mg</title>
            <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 210 mg</title>
            <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Through Month 12 of P1NP</title>
          <population>Randomized participants who received at least 10 doses of the assigned randomized treatment, had never received any dose of incorrect treatment, and had no missing P1NP measurements.</population>
          <units>ug*month/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554.5" lower_limit="523.0" upper_limit="585.9"/>
                    <measurement group_id="O2" value="539.2" lower_limit="506.4" upper_limit="572.0"/>
                    <measurement group_id="O3" value="638.5" lower_limit="607.9" upper_limit="669.2"/>
                    <measurement group_id="O4" value="708.3" lower_limit="676.6" upper_limit="740.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5084</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with the AUC of P1NP at month 12 as the dependent variable, and baseline P1NP and treatment (categorical) as the independent variables.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>-15.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.8</ci_lower_limit>
            <ci_upper_limit>30.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with the AUC of P1NP at month 12 as the dependent variable, and baseline P1NP and treatment (categorical) as the independent variables.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>84.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.1</ci_lower_limit>
            <ci_upper_limit>128.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with the AUC of P1NP at months 12 as the dependent variable, and baseline P1NP and treatment (categorical) as the independent variables.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>153.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>109.2</ci_lower_limit>
            <ci_upper_limit>198.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Romosozumab 70 mg</title>
          <description>Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Romosozumab 140 mg</title>
          <description>Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
        <group group_id="E4">
          <title>Romosozumab 210 mg</title>
          <description>Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

